Key points are not available for this paper at this time.
Major advances in the use of liposomes, conjugates, nanoparticles, and microspheres as vehicles delivering pharmacologic agents and enzymes to sites of disease have occurred in the past 10 years (11–32). Pegylated-STEALTH liposomal doxorubicin (Doxil, Caelyx) was the first liposomal
William C. Zamboni (Thu,) studied this question.